Cargando…
Early Wearing-Off Effect of OnabotulinumtoxinA in Chronic Migraine: A Prospective Real-Life Study
Objective: Chronic migraine (CM) is a significant public health problem that affects 2.2% of the global population. Onabotulinumtoxin A (OnabotA) is a safe and effective prophylactic treatment for patients with CM. The standard injection interval for OnabotA is 12 weeks. Nevertheless, some patients...
Autores principales: | Rodríguez-Montolio, Joana, Navarro-Pérez, María Pilar, Almeida-Zurita, Monserrath, Santos-Lasaosa, Sonia |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10455650/ https://www.ncbi.nlm.nih.gov/pubmed/37629402 http://dx.doi.org/10.3390/jcm12165360 |
Ejemplares similares
-
Effects of the onabotulinumtoxinA follow-up delay in migraine course during the COVID-19 lockdown
por: Gonzalez-Martinez, Alicia, et al.
Publicado: (2021) -
Cognitive effects of onabotulinumtoxinA in chronic migraine
por: Ho, Susan, et al.
Publicado: (2020) -
OnabotulinumtoxinA: Still the Present for Chronic Migraine
por: Baraldi, Carlo, et al.
Publicado: (2023) -
Real-World Economic Impact of OnabotulinumtoxinA in Patients With Chronic Migraine
por: Rothrock, John F, et al.
Publicado: (2014) -
Triptan efficacy does not predict onabotulinumtoxinA efficacy but improves with onabotulinumtoxinA response in chronic migraine patients
por: Eren, Ozan E., et al.
Publicado: (2020)